Walgreens, Rite Aid merger poised to boost digital health offerings

Beth Walsh | | Health Exec | Precision Medicine

Walgreens Boots Alliance will acquire rival drugstore chain Rite Aid for $9.4 billion, for a combined marketshare of 46.5 percent.

Walgreens has been more active on the technology side than Rite Aid, with it's impressive consumer rewards program, partnerships with Qualcomm Liffe, Misfit and UnitedHealthcare, content partnerships and electronic appointent booking.

Rite Aid brings some technological achievements to the table such as a health kiosk deal for tracking vital signs and integrated telemedicine. 

Learn more:

 
Walgreen's Rite Aid purchase could bring new digital health partners

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.